IBRXbenzinga

ImmunityBio Says Preparing To Submit sBLA In 2025 For Its Treatment Targeting Bacillus Calmette-guérin Unresponsive Non-muscle Invasive Bladder Cancer In The Papillary Indication

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 15, 2025 by benzinga

    ImmunityBio Says Preparing To Submit sBLA In 2025 For Its Treatment Targeting Bacillus Calmette-guérin Unresponsive Non-muscle Invasive Bladder Cancer In The Papillary Indication | IBRX Stock News | Candlesense